![The Protein That Ages You](https://cdn.slatesource.com/9/c/b/9cbb8f1a-1295-4df3-bfd9-306cd1ee1af0.webp) # The Protein That Ages You - [Made in Slatesource](https://slatesource.com/@steph/the-protein-that-ages-you) - By [Steph](https://slatesource.com/@steph) - Created on Aug 27, 2026 ## Eating 11% Less for Two Years Changes Immunity at Its Core A Yale team analysed plasma samples from 42 people who spent two years eating about 11 to 14 percent fewer calories. They screened more than 7,000 proteins across those samples. One stood out: complement component 3, known as C3, a protein produced by the immune system that rises steadily through adult life and sits at the root of chronic age-related inflammation. After two years of moderate calorie restriction, C3 levels dropped significantly. The drop was not explained by weight loss, which averaged around 18 pounds across the group. C3 fell in people who lost a lot of weight and in people who lost a little. The protein was tracking something about food intake itself rather than kilograms shed. [Nature Aging: Exoproteome of calorie-restricted humans identifies complement deactivation (Mishra, Kim, Dixit et al., 2026)](https://www.nature.com/articles/s43587-026-01107-0?utm_source=slatesource) ![](https://cdn.slatesource.com/9/c/b/9cbb8f1a-1295-4df3-bfd9-306cd1ee1af0.webp) ## C3 Is Not a Lab Curiosity: It Rises With Age and Drives Disease The complement system is one of the oldest parts of human immunity, a cascade of proteins that marks foreign invaders and cellular debris for destruction. C3 sits at the centre of that cascade. The problem is that C3 expression increases with normal aging in humans, monkeys, and mice. In older people, elevated C3 is negatively correlated with longevity and is linked to kidney disease, hippocampal decline, and dementia. Chronic low-grade inflammation driven by C3 and its active fragment C3a is what researchers now call inflammaging: the slow smouldering immune response that does not fight any infection but does damage tissue, impair cognition, and cut lifespan. It is distinct from the acute inflammation that heals a wound. Inflammaging cannot be seen or felt day to day but is measurable in blood and visible in the biology of every age-related disease. ## The Fat, Not the Liver: Where C3 Comes From in Aging The surprising finding from the Yale study is where calorie restriction suppresses C3. The liver makes most of the body's C3, but that is not where the action was. Lead researchers Manish Mishra and Hee-Hoon Kim used single-cell RNA sequencing to trace the source to a specific subset of macrophages, immune cells resident in visceral fat (white adipose tissue). These age-associated macrophages expand as we get older and pump C3a into the bloodstream. Calorie restriction appeared to quiet them down. The finding points to fat tissue as an immunometabolic control centre for aging, not merely a passive energy store. Human participants in the CALERIE trial 42 Proteins screened across plasma samples 7,000 plus Calorie reduction sustained over two years 11 to 14% Average weight lost over two years 18 pounds C3 reduction independent of weight loss confirmed Published in Nature Aging April 2026 > Aging is actually malleable and a process that can be targeted. ## You Do Not Have to Diet: Blocking C3 Directly Works Too In mice, the researchers did not need any dietary intervention. They simply neutralised C3a, the active fragment that macrophages secrete into visceral fat, and age-related inflammation was blocked. Inflammatory markers fell. The effect was essentially the same as calorie restriction, achieved pharmacologically. Dixit and his team are now investigating whether FDA-approved complement inhibitors, drugs already on the market for rare blood disorders, could reproduce this benefit in aging humans. The goal is not to disable the complement system, which is required for fighting infection, but to restore the balance that tips out of equilibrium with age. ## A Named Target at Last A 14% calorie cut sustained over years is genuinely hard for most people to maintain. If a targeted C3 inhibitor can deliver the same reduction in inflammaging without dietary discipline, the public health implications are substantial. GLP-1 drugs such as Ozempic already showed that pharmacology can achieve what diets mostly cannot. A complement inhibitor aimed at inflammaging would follow the same logic at a different mechanism. The CALERIE trial enrolled healthy non-obese adults in their 30s and 40s. Prior analyses found improvements in cardiometabolic markers, liver function, immune health, and epigenetic age. This paper adds a mechanism: the macrophage-C3a axis in visceral fat is an immunometabolic checkpoint that calorie restriction deactivates. There is now a named protein, a confirmed mouse model, and a candidate drug class. That is more structure than most aging research ever accumulates. [Yale School of Medicine: Cutting Calories to Slow Aging Without Compromising Health](https://medicine.yale.edu/news-article/cutting-calories-to-slow-aging-without-compromising-health/?utm_source=slatesource)